SNAI2 and chronic myelogenous leukemia, BCR-ABL1 positive: In contrast, in CML samples carrying a TKI resistant BCR-ABL mutation, SNAI2 expression was even more enhanced than in TKI sensitive samples and helped to drive cell survival in response to TKI (155).